Neumora Therapeutics, Inc. NMRA 深 滬
等待開盤 11-26 09:30:00 美东时间
2.25
+0.090
+4.17%
華盛通- 最 高2.255
- 今 開2.16
- 成交量 165.00万股
- 最 低 2.13
- 昨 收 2.16
- 總市值 3.65亿
- 52周最高 11.57
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 0.611
- 委 比 -69.68%
- 總股本 1.62亿
- 歷史最高 21.00
- 量 比 1.55
- 振 幅 5.79%
- 歷史最低 0.611
- 每 手 1
- 風險率 2.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Stifel Maintains Hold on Neumora Therapeutics, Raises Price Target to $3
Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises the price target from $2 to $3.
11-17 21:52
Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
Neumora Therapeutics shares are trading lower after the company reported worse-...
11-06 21:55
Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 4.79 percent. This is a 22.22 percent increase over losses of $(0.45) per share
11-06 20:22
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Neumora Reports Positive Preclinical Results for NMRA-215
Neumora Therapeutics, Inc. ( ($NMRA) ) has provided an update. On October 27, 2...
10-27 18:58
Neumora Announces Preclinical Data For NMRA-215, Showing Weight Loss Of Up To 19% As Monotherapy With Semaglutide-Like Induction; Plans To Initiate Phase 1 Clinical Study In Q1 2026
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutideClass-leading
10-27 18:36
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Neumora Therapeutics announced positive preclinical data for NMRA-215, a potentially best-in-class, brain-penetrant, oral NLRP3 inhibitor, showing up to 19% weight loss as monotherapy and up to 26% in combination with semaglutide. NMRA-215's strong brain penetration and pharmacology contribute to its class-leading weight loss. Phase 1 clinical studies are planned for Q1 2026.
10-27 10:30
美股牛股 | VTYX大涨71%！新药研究取得积极结果；SEV转型为公益公司，涨近58%
VTYX大涨71%！新药在肥胖和心血管风险因素患者中的2期研究取得积极结果；SEV转型为公益公司，涨近58%>>
10-24 15:16
